Free Trial
Uy Ear

Uy Ear Analyst Performance

Vice President US Healthcare - Biotechnology at Mizuho

Uy Ear is a stock analyst at Mizuho in the medical sector, covering 6 publicly traded companies. Over the past year, Uy Ear has issued 7 stock ratings, including buy and hold recommendations. While full access to Uy Ear's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Uy Ear's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 3 Years
Buy Recommendations
70.00% 7 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy70.0%7 ratings
Hold30.0%3 ratings
Sell0.0%0 ratings

Out of 10 total stock ratings issued by Uy Ear at Mizuho, the majority (70.0%) have been Buy recommendations, followed by 30.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
83.3% of companies on NASDAQ
5 companies
NYSE
16.7% of companies on NYSE
1 company

Uy Ear, an analyst at Mizuho, currently covers 6 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Uy Ear of Mizuho specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
66.7%
PHARMACEUTICAL PREPARATIONS
1 company
16.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
16.7%

About Uy Ear

Uy joined Mizuho in September 2019 as a vice president based in New York, covering the pharmaceutical and biotechnology sectors. Prior to Mizuho, Uy was at Credit Suisse where he covered large cap and specialty pharmaceuticals. Before Credit Suisse, he worked in health care consulting and at Piper and UBS, where he was a key member of Institutional Investor ranked teams. Uy has a BA from the University of Chicago and an MBA from the Olin School of Business.

Uy Ear's Ratings History at Mizuho

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
8/7/2025Boost Price Target$23.80$24.00Neutral
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
8/5/2025Initiated Coverage$12.54$38.00Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7/21/2025Reiterated Rating$14.07$14.00Neutral
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/18/2025Lower Price Target$21.01$40.00Outperform
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
5/19/2025Boost Price Target$21.76$23.00Neutral
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
4/21/2025Initiated Coverage$17.02$51.00Outperform
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2/26/2025Boost Price Target$12.76$21.00Outperform